Clinical trials: Neurocognitive Disorders, Mild
Mild Cognitive Impairment
Sound and Music for Mild Cognitive Impairment
Emerging studies in humans found that 40 Hz sound induces neural gamma oscillation and enhanced cognitive function in older adults with and without Alzheimer's Disease.
- Trial name
- NCT05064007
- Testing
- A: 40 Hz music, B: 40 Hz sound, C: Preferred music
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Alzheimer Disease
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
The study is to evaluate the safety, tolerability and whether there is an immune system response to multiple doses of ACC-001 with or without the use of a substance that may increase the response to the drug.
- Trial name
- NCT00752232
- Testing
- ACC-001, QS-21, PBS
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Alzheimer's Disease
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
- Trial name
- MCI (NCT02016560)
- Testing
- florbetapir F 18, Flortaucipir F18, Brain PET Scan
- Where
- 27 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment
Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults
Cognitive impairment is also a major risk factor for development of dementia later in life. Findings from the investigators studies suggest that the carotenoids, lutein and zeaxanthin may be important in cognitive function in the…
- Trial name
- NCT01620567
- Testing
- avocado, potato or chickpea
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tufts University
Alzheimer's Disease
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease
Part 1 of this study will be conducted to determine the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of TB006, as well as the maximum tolerated dose of TB006, and to assess the immunogenicity of TB006…
- Trial name
- NCT05074498
- Testing
- TB006
- Where
- 18 sites in United States
- Volunteers
- 154 people
- Sponsor
- TrueBinding, Inc.
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Alzheimer Disease
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00676143
- Testing
- bapineuzumab
- Where
- 288 sites in United States, Argentina and 22 more
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Alzheimer's Disease
Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00381238
- Testing
- rosiglitazone
- Where
- 7 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Mild Cognitive Impairment, Caregiver Burnout
Improving Physical Activity With Cognitive Impairment
Individuals with mild cognitive impairment are often physically inactive and at risk for progressing to dementia. Physical inactivity is considered a modifiable risk factor for dementia.
- Trial name
- NCT05370118
- Testing
- Telerehabilitation physical activity behavioral (TPAB) intervention
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Creighton University
Alzheimer Disease
The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the modulating effect of galantamine on circadian rhythm in patients with moderate Alzheimer's disease.
- Trial name
- NCT01181921
- Testing
- Galantamine
- Where
- Spain
- Volunteers
- 1 people
- Sponsor
- Janssen-Cilag, S.A.
Mild Traumatic Brain Injury, Concussion
Neurocognitive Evaluation of Mild Traumatic Brain Injury in the Hospitalized Pediatric Population
Brain injuries from trauma are common in children, often resulting in death and disability. Most brain injuries are minor, yet their treatment can be challenging.
- Trial name
- NCT00715949
- Testing
- Immediate Post-concussion Assessment and Cognitive Testing
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Children's Hospital of Philadelphia
Alzheimer's Disease
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
The purpose of the study is to determine whether memantine delays the progression of driving impairment in patients with mild Alzheimer's Disease (AD).
- Trial name
- NCT00476008
- Testing
- Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Florida Atlantic University
Alzheimer Disease, Mild Cognitive Impairment
Noninvasive Brain Stimulation in Mild Cognitive Impairment and Dementia
The research objective of this study is to examine the efficacy of HD-tDCS to the preSMA/DACC region and its influence on verbal episodic memory in patients with MCI or dementia after 10 sessions of HD-tDCS.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT05270408
- Testing
- Active Transcranial direct current stimulation (STARStim 8)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer Disease
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, plus QS-21 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00960531
- Testing
- ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
- Where
- 28 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimer's Disease
Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's disease (AD) is the most common cause of progressive cognitive decline in the United States. AD is characterized by severe impairments in learning, memory and other cognitive abilities that significantly interfere…
- Trial name
- NCT01202994
- Testing
- 18F-Flutemetamol
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Utah
Alzheimer Disease
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets
This study assessed the Hr QoL (Health related Quality of life) of subjects with mild to moderate AD, who received ARICEPT under usual clinical practice.
- Trial name
- QUEST (NCT01089582)
- Testing
- No intervention
- Where
- 29 sites in Greece
- Volunteers
- 628 people
- Sponsor
- Pfizer
Alzheimer Disease
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.
- Trial name
- NCT03443973
- Testing
- Gantenerumab
- Where
- 155 sites in United States, Argentina and 17 more
- Volunteers
- 975 people
- Sponsor
- Hoffmann-La Roche
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)
This study consists of Part I and an optional Part II. The purpose of Part I is to compare the plasma pharmacokinetics of verubecestat (MK-8931) following administration of a single oral dose of 40 mg MK-8931 to participants with…
- Conditions
- Amnestic Mild Cognitive Impairment, Alzheimer's Disease, Prodromal Alzheimer's Disease
- Trial name
- NCT02910739
- Testing
- MK-8931
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities.
- Trial name
- NCT03482167
- Testing
- Niagen®
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Delaware
Engagement, Patient, Mood
SimpleC Wellness Platform With Social Robot Interaction
This implementation study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Mood, Quality of Life, Aging
- Trial name
- NCT05296239
- Testing
- SimpleC Wellness Platform with Social Robot Interaction
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- SimpleC, LLC